These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 20817406)
1. Sunitinib for the treatment of metastatic renal cell carcinoma. Oudard S; Beuselinck B; Decoene J; Albers P Cancer Treat Rev; 2011 May; 37(3):178-84. PubMed ID: 20817406 [TBL] [Abstract][Full Text] [Related]
2. Sunitinib for the management of advanced renal cell carcinoma. Escudier B Expert Rev Anticancer Ther; 2010 Mar; 10(3):305-17. PubMed ID: 20214511 [TBL] [Abstract][Full Text] [Related]
3. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma. Chouhan JD; Zamarripa DE; Lai PH; Oramasionwu CU; Grabinski JL J Oncol Pharm Pract; 2007 Mar; 13(1):5-15. PubMed ID: 17621562 [TBL] [Abstract][Full Text] [Related]
4. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Adams VR; Leggas M Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency. Kim KH; Kim HY; Kim HR; Sun JM; Lim HY; Lee HJ; Lee S; Bae WK; Rha SY; ; Eur J Cancer; 2014 Mar; 50(4):746-52. PubMed ID: 24332573 [TBL] [Abstract][Full Text] [Related]
6. [Sunitinib--from paradigm shift to standard treatment of metastatic renal cell carcinoma]. Bergmann L Onkologie; 2010; 33 Suppl 1():2-4. PubMed ID: 20164668 [TBL] [Abstract][Full Text] [Related]
7. [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)]. Siebels M; Staehler M; Hegele A; Varga Z; Oberneder R; Doehn C; Heinzer H; Aktuelle Urol; 2010 Mar; 41(2):122-30. PubMed ID: 19937556 [TBL] [Abstract][Full Text] [Related]
8. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Gore ME; Szczylik C; Porta C; Bracarda S; Bjarnason GA; Oudard S; Lee SH; Haanen J; Castellano D; Vrdoljak E; Schöffski P; Mainwaring P; Hawkins RE; Crinò L; Kim TM; Carteni G; Eberhardt WE; Zhang K; Fly K; Matczak E; Lechuga MJ; Hariharan S; Bukowski R Br J Cancer; 2015 Jun; 113(1):12-9. PubMed ID: 26086878 [TBL] [Abstract][Full Text] [Related]
9. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. Cella D; Li JZ; Cappelleri JC; Bushmakin A; Charbonneau C; Kim ST; Chen I; Motzer RJ J Clin Oncol; 2008 Aug; 26(22):3763-9. PubMed ID: 18669464 [TBL] [Abstract][Full Text] [Related]
10. Current evidence and the evolving role of sunitinib in the management of renal cell carcinoma. Noronha V; Joshi A; Bakshi G; Tongaonkar H; Prabhash K Indian J Cancer; 2016; 53(1):102-8. PubMed ID: 27146754 [TBL] [Abstract][Full Text] [Related]
12. Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions. Kruse V; Somers A; Van Bortel L; De Both A; Van Belle S; Rottey S J Clin Pharm Ther; 2014 Jun; 39(3):259-65. PubMed ID: 24417304 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial. Sternberg CN; Calabrò F; Bracarda S; Cartenì G; Lo Re G; Ruggeri EM; Basso U; Gasparini G; Ciuffreda L; Ferrari V; Bonetti A; Fea E; Gasparro D; Tassinari D; Labianca R; Masini C; Fly K; Zhang K; Hariharan S; Capaccetti B; Porta C Oncology; 2015; 88(5):273-80. PubMed ID: 25592399 [TBL] [Abstract][Full Text] [Related]
15. Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study. Oudard S; Geoffrois L; Guillot A; Chevreau C; Deville JL; Falkowski S; Boyle H; Baciuchka M; Gimel P; Laguerre B; Laramas M; Pfister C; Topart D; Rolland F; Legouffe E; Denechere G; Amela EY; Abadie-Lacourtoisie S; Gross-Goupil M Eur J Cancer; 2016 Jul; 62():28-35. PubMed ID: 27192659 [TBL] [Abstract][Full Text] [Related]
16. Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice. Schmidinger M; Arnold D; Szczylik C; Wagstaff J; Ravaud A Cancer Invest; 2010 Oct; 28(8):856-64. PubMed ID: 20504222 [TBL] [Abstract][Full Text] [Related]
17. Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib? Keizman D; Rouvinov K; Sella A; Gottfried M; Maimon N; Kim JJ; Eisenberger MA; Sinibaldi V; Peer A; Carducci MA; Mermershtain W; Leibowitz-Amit R; Weitzen R; Berger R Cancer Res Treat; 2016 Jan; 48(1):281-7. PubMed ID: 25761478 [TBL] [Abstract][Full Text] [Related]
18. Expanding the boundaries of clinical practice: building on experience with targeted therapies. Sternberg CN Ann Oncol; 2009 May; 20 Suppl 1():i1-6. PubMed ID: 19430002 [TBL] [Abstract][Full Text] [Related]
19. Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma. Raphael J; Thawer A; Bjarnason GA Urol Oncol; 2018 Jan; 36(1):12.e1-12.e6. PubMed ID: 28966072 [TBL] [Abstract][Full Text] [Related]
20. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors. Livne-Segev D; Gottfried M; Maimon N; Peer A; Neumann A; Hayat H; Kovel S; Sella A; Mermershtain W; Rouvinov K; Boursi B; Weitzen R; Berger R; Keizman D Isr Med Assoc J; 2014 Jun; 16(6):347-51. PubMed ID: 25058995 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]